



PATENT
CASE AL01583K1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

-----X
In re Application of:

Robert G. Aslanian et al

For Patent For:

Indole Derivatives Useful as
Histamine H₃ Antagonists

Examiner: To be assigned

Art Unit: To be assigned

Serial No.: 10/600,674

Filing Date: June 20, 2003
-----X:

Schering-Plough Corporation
Kenilworth, New Jersey 07033-0530

Commissioner for Patents
PO Box 1450
Alexandria VA 22313-1450

INFORMATION DISCLOSURE STATEMENT


Sir:

This statement is made in compliance with 37 C.F.R. 1.56, 1.97 and 1.98. Applicants enclose a Form PTO-1449 (one page) listing publications known to applicants that may be relevant to this application. This Statement is being filed within three months of filing the application.


Publications AA, AB, AN-AQ and AR-AT were cited in the specification. Publication AL is the published equivalent of PCT US01/32151, and AM is the equivalent of US 10/095,134, both cited on page 3 of the specification. References AU and AV are co-owned, co-pending applications relating to benzimidazole and benzimidazolone derivatives useful as H₃ antagonists. The applications, both filed on April 16, 2003, are not yet electronically available.

Copies of the publications are attached.

The examiner is respectfully requested to examine the publications, initial the form PTO-1449 and return a copy of the initialed form to applicants.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Commissioner for Patents, Alexandria VA 22313-1450 on July 24, 2003	
Anita W. Magatti	
Registered Representative	
 Signature	7/24/03 Date

Respectfully submitted,


Anita W. Magatti
Reg. No. 29,825
Attorney for Applicants
(908) 298-5067



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.:
AL01583K1SERIAL NO.:
10/600,674APPLICANT:
Robert G. Aslanian et al.FILING DATE:
06/20/2003

GROUP:

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AA	5,869,479	02/09/99	William Kreutner <i>et al.</i>	514	212	
	AB	5,846,982	12/08/98	Audia <i>et al.</i>	514	318	
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO
	AL	WO 02/32893	4/25/02	WIPO				
	AM	WO 02/072570	9/19/02	WIPO				
	AN	WO 98/06394	2/19/98	WIPO				
	AO	WO 01/46181	06/28/01	WIPO				
	AP	EP 0 470 039	12/07/94	EPO				
	AQ	JP 63-227573	09/21/88	Japan				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AR	Rizzo <i>et al.</i> , <i>European Journal of Pharmacology</i> , Vol. 294 (1995) pgs. 329-335
AS	G. Heinisch <i>et al.</i> , <i>Monatshefte fur Chemie</i> , Vol. 104 (1973) pgs. 1372-1382
AT	Obase <i>et al.</i> , <i>J. Heterocyclic Chemistry</i> , Vol. 20 (1983) pgs. 565-573
AU	US Application 10/417, 391 pgs. 1-127
AV	US Application 10/414, 943 pgs. 1-87
AW	
AX	
AY	
AZ	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.